To OTC Journal Members: 

Lots of news today, so let's get to it.
 

BioCurex (OTC BB: BOCX): Your Questions Answered

My little $.07 idea from last week has turned into a barn burner. Little known and treacherously speculative BOCX, which I published on last week at $.07, is now $.22- no big deal- $.08? Consider it's more than a triple in one week.

Just the beginning of the resurgence for this highly speculative and treacherous little stock. This is one of those situations where the stock has been so blown out it could trade up more rather easily.

I wanted to clarify one major issue. Many of you have been emailing me- asking me if the company has an FDA approval for it's highly sensitive cancer test. The answer is both yes and no.

What they have is an FDA exemption- anotherwords, they don't need an approval, for a version of their test for tissue samples. However, the commercial market is looking for a blood test version, and they will have to go through an FDA study to get it. It won't be anything like an FDA approval for a new drug- probably just a six month test to prove it works.

After all, they are not puttting anything in the body, and they are not treating anybody. They are just trying to commercialize a technology that will allow them participate in the single most important factor in cancer therapy- early detection.

There was news today- lest you worry about them having money, they just completed a small private placement for $400,000- this is a low overhead operation, so that money will go a long way. Click here if you want to read the news.

Here's a bit of a longer term chart. I provide this so you can get the big picture. The stock has turned up, but look where it's come from over the past year. Down from $.50.

And yes, both Abbot Labs (NYSE: ABT), and Inverness Medical (NYSE: IMA) have signed on and licensed their technology. 

Short term price target: $.30.- that's about 66% higher than today's levels.
 

Cel-Sci (AMEX: CVM) Cashes up

Just a quick comment. Just as I predicted, CVM is using its new found fame to cash up so it can get into Phase III clinical trials on Multikine, where CVM's real future is.

This one has been a barn burner for us. Up from my initial level of $.36 in June. How do you beat that? Today, CVM announced it was raising $20 million priced at $1.40 per share. Can you say Phase III clinical trial? Some of the big boys are probably already shorting out of the common stock so they can keep the attached warrant.

This will put a temporary ceiling on the stock, but once the market absorbs the short term supply, I suspect higher levels will be at hand. Someone thinks they can put in $20 million, and make money from $1.40. 
 

Force Protection (NASDAQ: FRPT): Finally Making Some Money

Force Protection- which I wrote about back in July 18 at $5.20, is finding a bid now. This stock was a monster a couple of years ago- $2 to $25. Then a fallen angel. If you're in, we're now up 10%.

They made their name with revolutionary new armor for the Humvees over in the middle east. Their technology provides far better deflection technology for land mines.

Last week, they rolled out a new prototype which can be used to replace the Humvee, and the market is starting to take notice.

The stock is down from $9 when they lost a big military contract to a competitor. Here's the inside scoop- the competitor is likely going to have to come to them for part of the contract, and the market in typical fashion has over reacted.

This stock is going to want to try to fill that gap created in July. There's three points to be made here.

Motley Fool has featured this one of late. Buy it for $9 later this year or early next.

Home Page : www.otcjournal.com
Email Questions or Comments To: editor@otcjournal.com